Abstract
Nanoparticulate carriers of anthracyclines are being developed with the aim of improving the pharmacokinetic or pharmacodynamic behavior of these drugs. To understand how the drug reaches its nuclear targets, we have developed two methods that allow the quantification of the interaction between an anthracycline and cellular DNA: (1) by direct evaluation of the quenching of the drug into DNA and (2) by the measurement of Hoechst 33258 fluorescence associated with its displacement from DNA-binding sites for which it competes with the anthracycline. We show that the intracellular accumulation and DNA binding of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres (dox-NS) and of daunorubicin bound to polyglutamic acid are reduced by 30%–40% in comparison with those obtained for free doxorubicin (dox) and daunorubicin, respectively. The results obtained with dox or NS-dox are not modified by prior incubation with either of these compounds. The two methods yielded similar results, and we conclude that either technique is applicable to the evaluation of the interaction of carrierbound anthracyclines with cellular DNA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bennis S, Garcia C, Robert J (1993) Aspects of the cellular pharmacology ofN-1-leucyldoxorubicin in human tumor cell lines. Biochem Pharmacol 45: 1929
Bennis S, Chapey C, Couvreur P, Robert J (1994) Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer 30: 89
Bogush TA, Baranov EP, Kozovez AB, Tankovich NI (1990) Intravital estimation of doxorubicin accumulation in various types of cell cultures. Antibiot Khimiother 35: 16
Bogush TA, Baranov EP, Egudina SV, Tankovich NI (1992) Quantitative estimation of anthracycline antibiotic binding with DNA. Bull Eksp Biol Med 6: 636
Couvreur P, Roblot-Treupel L, Poupon MF, Brasseur P, Puisieux F (1990) Nanoparticles as microcarriers for anticancer drugs. Adv Drug Deliv 5: 209
Duncan R, Seymour LW, O'Hare KB, Flanagan PA, Wedge S, Hume IC, Ulbrich K, Strohalm J, Subr V, Spreafico F, Grandi M, Ripamonti M, Farao M, Suarato A (1992) Preclinical evaluation of polymer-bound doxorubicin. J Control Rel 19: 331
Egudina CV, Baranov EP, Bogush TA (1992) Use of Hoechst fluorescent dye 33258 for quantitative estimation of intracellular anthracycline binding to DNA. Antibiot Khimiother 37: 21
Fritzer M, Barabas K, Szüts V, Berczi A, Szekeres T, Faulk WP, Goldenberg H (1992) Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int J Cancer 52: 619
Gabizon A, Shiota R, Papahadjopoulos D (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 81: 1484
Gahrton G, Tidefelt U, Paul C, Bjorkholm M, Grimfors G, Hast R, Juliusson G, Jarnmark M, Killander A, Kimby E, Liliemark J, Lindquist R, Lockner D, Lonqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt AM, Sundstrom C, Uden AM, Wadman B, Oberg G, Ost A (1992) DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia. Leukemia 6: 89
Gigli M, Rasonaivo TWD, Millot JM, Jeannesson P, Rizzo V, Jardillier JC, Arcamone F, Manfait M (1989) Correlation between growth inhibition and intracellular doxorubicin and 4′-deoxy-4′-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res 49:560
Huet S, Schott B, Robert J (1992) P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. Br J Cancer 65:538
Oudard S, Thierry A, Jorgensen TJ, Rahman A (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259
Ramu A, Pollard HB, Rosario LM (1989) Doxorubicin resistance in P388 leukemia. Evidence for reduced drug influx. Int J Cancer 44:539
Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracylines. Cancer Surv 17:219
Schott B, Robert J (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and-resistant rat glioblastoma cells. Biochem Pharmacol 38:167
Tarasiuk J, Frezard F, Garnier-Suillerot A, Gattegno L (1989) Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta 1013:109
Yeh MY, Roffler SR, Yu MH (1991) Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 51:274
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bogush, T., Smirnova, G., Shubina, I. et al. Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines. Cancer Chemother. Pharmacol. 35, 501–505 (1995). https://doi.org/10.1007/BF00686835
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686835